The Oncology Institute Inc. reports Q3 revenue growth and raises 2025 guidance

Reuters11-14

<a href="https://laohu8.com/S/TOI">The Oncology Institute</a> Inc. reports Q3 revenue growth and raises 2025 guidance

The Oncology Institute Inc. reported a 13% increase in fee-for-service revenue for the third quarter of 2025 compared to the same period in 2024, driven by organic growth in Florida and Oregon. Retail Pharmacy and Dispensary operations generated $75.9 million in revenue and $12.8 million in gross profit during the quarter. The company expects adjusted EBITDA of approximately $0 to $2 million in the fourth quarter of 2025 and projects free cash flow between negative $12 million and negative $21 million for the year. Cash and cash equivalents stood at $27.7 million as of September 30, 2025. Business developments included setting new fill records in the pharmacy segment, signing new in-network MSO providers in Florida, and opening a new pharmacy location in the state.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. The Oncology Institute Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9575480-en) on November 13, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2583314514?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-14 05:07","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2583314514","market":"fut","top_or_hot":-1,"title":"The Oncology Institute Inc. reports Q3 revenue growth and raises 2025 guidance","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/TOI\">The Oncology Institute</a> Inc. reports Q3 revenue growth and raises 2025 guidance\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        The Oncology Institute Inc. reported a 13% increase in fee-for-service revenue for the third quarter of 2025 compared to the same period in 2024, driven by organic growth in Florida and Oregon. Retail Pharmacy and Dispensary operations generated $75.9 million in revenue and $12.8 million in gross profit during the quarter. The company expects adjusted EBITDA of approximately $0 to $2 million in the fourth quarter of 2025 and projects free cash flow between negative $12 million and negative $21 million for the year. Cash and cash equivalents stood at $27.7 million as of September 30, 2025. Business developments included setting new fill records in the pharmacy segment, signing new in-network MSO providers in Florida, and opening a new pharmacy location in the state.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. The Oncology Institute Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9575480-en) on November 13, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>The Oncology Institute Inc. reports Q3 revenue growth and raises 2025 guidance</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThe Oncology Institute Inc. reports Q3 revenue growth and raises 2025 guidance\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-14 05:07</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/TOI\">The Oncology Institute</a> Inc. reports Q3 revenue growth and raises 2025 guidance\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        The Oncology Institute Inc. reported a 13% increase in fee-for-service revenue for the third quarter of 2025 compared to the same period in 2024, driven by organic growth in Florida and Oregon. Retail Pharmacy and Dispensary operations generated $75.9 million in revenue and $12.8 million in gross profit during the quarter. The company expects adjusted EBITDA of approximately $0 to $2 million in the fourth quarter of 2025 and projects free cash flow between negative $12 million and negative $21 million for the year. Cash and cash equivalents stood at $27.7 million as of September 30, 2025. Business developments included setting new fill records in the pharmacy segment, signing new in-network MSO providers in Florida, and opening a new pharmacy location in the state.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. The Oncology Institute Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9575480-en) on November 13, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IE00B3QW5Z07.USD","symbol_name":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251113:nNDL5zf5DJ:1","article_id":"2583314514","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2583314514","pubTimestamp":1763068037,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"The Oncology Institute Inc. reported a 13% increase in fee-for-service revenue for the third quarter of 2025 compared to the same period in 2024, driven by organic growth in Florida and Oregon. Retail Pharmacy and Dispensary operations generated $75.9 million in revenue and $12.8 million in gross profit during the quarter. The company expects adjusted EBITDA of approximately $0 to $2 million in the fourth quarter of 2025 and projects free cash flow between negative $12 million and negative $21 million for the year. Cash and cash equivalents stood at $27.7 million as of September 30, 2025. Business developments included setting new fill records in the pharmacy segment, signing new in-network MSO providers in Florida, and opening a new pharmacy location in the state.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","BK4588":"碎股","NDAQ":"纳斯达克OMX交易所","BK4585":"ETF&股票定投概念","BK4112":"金融交易所和数据","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","LU0314104364.USD":"MANULIFE GF AMERICAN GROWTH \"AA\" (USD) INC","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","TOI":"The Oncology Institute","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","BK4185":"保健护理机构","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC"},"translate_title":"肿瘤研究所报告第三季度收入增长并提高2025年指引","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TOI":0.9,"NDAQ":0.9},"content_text":"The Oncology Institute Inc. reports Q3 revenue growth and raises 2025 guidance\n    \n\n        The Oncology Institute Inc. reported a 13% increase in fee-for-service revenue for the third quarter of 2025 compared to the same period in 2024, driven by organic growth in Florida and Oregon. Retail Pharmacy and Dispensary operations generated $75.9 million in revenue and $12.8 million in gross profit during the quarter. The company expects adjusted EBITDA of approximately $0 to $2 million in the fourth quarter of 2025 and projects free cash flow between negative $12 million and negative $21 million for the year. Cash and cash equivalents stood at $27.7 million as of September 30, 2025. Business developments included setting new fill records in the pharmacy segment, signing new in-network MSO providers in Florida, and opening a new pharmacy location in the state.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. The Oncology Institute Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9575480-en) on November 13, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2583314514","isCrawlerRequest":true}